CanBas Company Description

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients.

It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors.

The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

CanBas Co., Ltd.

Country	Japan
Founded	2000
Industry	Biotechnology
Sector	Healthcare
Employees	11
CEO	Takumi Kawabe

Contact Details

Address: 2-2-1, Otemachi Numazu, 410-0801 Japan
Phone	81 55 954 3666
Website	canbas.co.jp

Stock Details

Ticker Symbol	4575
Exchange	Tokyo Stock Exchange
Fiscal Year	July - June
Reporting Currency	JPY
ISIN Number	JP3244570002
SIC Code	2836

Key Executives

Name	Position
Takumi Kawabe	Chief Executive Officer
Makoto Katozumi	Chief Financial Officer